Novel drug delivery methods for improving efficacy of endometriosis treatments

References

• Missmer SA, Cramer DW. The epidemiology of endometriosis. Obstet Gynecol Clin North Am. 2003;30:1–19. vii.
   PubMed Web of Science ®Google Scholar
• Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362:2389–2398.
   PubMed Web of Science ®Google Scholar
• Morotti M, Remorgida V, Venturini PL, et al. Endometriosis in menopause: a single institution experience. Arch Gynecol Obstet. 2012;286:1571–1575.
   PubMed Web of Science ®Google Scholar
• Johnson NP, Hummelshoj L, Adamson GD, et al. World endometriosis society consensus on the classification of endometriosis. Hum Reprod. 2017;32:315–324.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitale SG, Trovato MA, et al. Full-thickness excision versus shaving by laparoscopy for intestinal deep infiltrating endometriosis: rationale and potential treatment options. BioMed Res Int. 2016;2016:3617179.
   PubMed Web of Science ®Google Scholar
• Raffaelli R, Garzon S, Baggio S, et al. Mesenteric vascular and nerve sparing surgery in laparoscopic segmental intestinal resection for deep infiltrating endometriosis. Eur J Obstet Gynecol Reprod Biol. 2018;231:214–219.
   PubMed Web of Science ®Google Scholar
• Remorgida V, Ferrero S, Fulcheri E, et al. Bowel endometriosis: presentation, diagnosis, and treatment. Obstet Gynecol Surv. 2007;62:461–470.
   PubMed Web of Science ®Google Scholar
• Baggio S, Pomini P, Zecchin A, et al. Delivery and pregnancy outcome in women with bowel resection for deep endometriosis: a retrospective cohort study. Gynecol Surg. 2015;12:279–285.
   Web of Science ®Google Scholar
• Barra F, Scala C, Biscaldi E, et al. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transformation and fertility. Hum Reprod Update. 2018 Nov;1(24):710–730.
   Google Scholar
• Butticè S, Laganà AS, Mucciardi G, et al. Different patterns of pelvic ureteral endometriosis. What is the best treatment? Results of a retrospective analysis. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol. 2016;88:266–269.
   PubMedGoogle Scholar
• Leone Roberti Maggiore U, Ferrero S, Candiani M, et al. Bladder endometriosis: a systematic review of pathogenesis, diagnosis, treatment, impact on fertility, and risk of malignant transformation. Eur Urol. 2017;71:790–807.
   PubMed Web of Science ®Google Scholar
• Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev. 2004;CD003678.
   PubMedGoogle Scholar
• Jacobson TZ, Duffy JM, Barlow D, et al. Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database Syst Rev. 2010;CD001398.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Alessandri F, Racca A, et al. Treatment of pain associated with deep endometriosis: alternatives and evidence. Fertil Steril. 2015;104:771–792.
   PubMed Web of Science ®Google Scholar
• Somigliana E, Benaglia L, Vigano’ P, et al. Surgical measures for endometriosis-related infertility: A plea for research. Placenta. 2011;32:S238–S242.
   PubMed Web of Science ®Google Scholar
• Sleiman Z, Karaman E, Terzic M, et al. Fertility preservation in benign gynecological diseases: current approaches and future perspectives. J Reprod Infertil. 2019;20:201.
   PubMedGoogle Scholar
• Apostolopoulos NV, Alexandraki KI, Gorry A, et al. Association between chronic pelvic pain symptoms and the presence of endometriosis. Arch Gynecol Obstet. 2016;293:439–445.
   PubMed Web of Science ®Google Scholar
• Howard FM. Endometriosis and mechanisms of pelvic pain. J Minim Invasive Gynecol. 2009;16:540–550.
   PubMed Web of Science ®Google Scholar
• Coxon L, Horne AW, Vincent K. Pathophysiology of endometriosis-associated pain: A review of pelvic and central nervous system mechanisms. Best Pract Res Clin Obstet Gynaecol. 2018;51:53–67.
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Orellana R, et al. Endometriosis and infertility. Panminerva Med. 2016;58:143–150.
   PubMed Web of Science ®Google Scholar
• Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–412.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitale SG, Granese R, et al. Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside. Expert Opin Drug Metab Toxicol. 2017;13:593–596.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Garzon S, Götte M, et al. The pathogenesis of endometriosis: molecular and cell biology insights. Int J Mol Sci. 2019;20:5615.
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller MD, Bersinger NA, et al. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. Gynecol Endocrinol. 2017;33:712–715.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018;14:399–415.
   PubMed Web of Science ®Google Scholar
• Cetel NS, Rivier J, Vale W, et al. The dynamics of gonadotropin inhibition in women induced by an antagonistic analog of gonadotropin-releasing hormone. J Clin Endocrinol Metab. 1983;57:62–65.
   PubMed Web of Science ®Google Scholar
• Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010;CD008475.
   PubMed Web of Science ®Google Scholar
• Della Corte L, Barra F, Mercorio A, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020;16:759-768.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018;19:1109–1125.
   PubMed Web of Science ®Google Scholar
• Riemma G, Laganà AS, Schiattarella A, et al. Ion channels in the pathogenesis of endometriosis: a cutting-edge point of view. Int J Mol Sci. 2020;21:1114.
   PubMed Web of Science ®Google Scholar
• Della Corte L, Noventa M, Ciebiera M, et al. Phytotherapy in endometriosis: an up-to-date review. J Complement Integr Med. 2019. DOI:10.1515/jcim-2019-0084
   Google Scholar
• Laganà AS, Garzon S, Casarin J, et al. Know your enemy: potential role of cabergoline to target neoangiogenesis in endometriosis. J Invest Surg. 2020;11:1-2.
   Web of Science ®Google Scholar
• Becker CM, Gattrell WT, Gude K, et al. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017;108:125–136.
   PubMed Web of Science ®Google Scholar
• Bradbury J. Beyond pills and jabs. Researchers develop new ways to get drugs to the right place at the right time. Lancet Lond Engl. 2003;362:1984–1985.
   PubMed Web of Science ®Google Scholar
• Friend DR. Development of controlled release systems over the past 50years in the area of contraception. J Control Release Off J Control Release Soc. 2016;240:235–241.
   PubMed Web of Science ®Google Scholar
• Friend DR. Drug delivery for the treatment of endometriosis and uterine fibroids. Drug Deliv Transl Res. 2017;7:829–839.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. Expert Opin Pharmacother. 2010 May;11:1123–1134.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Abbamonte LH, Anserini P, et al. Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv. 2005;60:817–826.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005;84:1375–1387.
   PubMed Web of Science ®Google Scholar
• Lete I, Dueñas JL, Esplugues JV, et al. Is the vagina an adequate route for the administration of hormonal contraceptives? Curr Drug Metab. 2010;11:839–849.
   PubMed Web of Science ®Google Scholar
• Barriga Pooley P, Von Hoveling A, Galán G, et al. Analysis and new contraception frontiers with combined vaginal rings. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2020;36:475-478.
   Google Scholar
• Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233–242.
   PubMed Web of Science ®Google Scholar
• van den Heuvel MW, van Bragt AJM, Alnabawy AKM, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–174.
   PubMed Web of Science ®Google Scholar
• Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 2001;75:865–870.
   PubMed Web of Science ®Google Scholar
• Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010;82:418–427.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;CD003552.
   PubMed Web of Science ®Google Scholar
• Buggio L, Lazzari C, Monti E, et al. “Per vaginam” topical use of hormonal drugs in women with symptomatic deep endometriosis: a narrative literature review. Arch Gynecol Obstet. 2017;296:435–444.
   PubMed Web of Science ®Google Scholar
• De Ziegler D, Bulletti C, De Monstier B, et al. The first uterine pass effect. Ann N Y Acad Sci. 1997;828:291–299.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010;93:2150–2161.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014;93:239–247.
   PubMed Web of Science ®Google Scholar
• Mizutani T, Nishiyama S, Amakawa I, et al. Danazol concentrations in ovary, uterus, and serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository. Fertil Steril. 1995;63:1184–1189.
   PubMed Web of Science ®Google Scholar
• Spooner JB. Classification of side-effects to danazol therapy. J Int Med Res. 1977;5(Suppl 3):15–17.
   PubMedGoogle Scholar
• Igarashi M. A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application. Asia Oceania J Obstet Gynaecol. 1990;16:1–12.
   PubMedGoogle Scholar
• Igarashi M, Iizuka M, Abe Y, et al. Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod Oxf Eng. 1998;13:1952–1956.
   PubMed Web of Science ®Google Scholar
• Razzi S, Luisi S, Calonaci F, et al. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril. 2007;88:789–794.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SM, Tolasaria A, Khan B. Vaginal danazol for the treatment of endometriosis-related pelvic pain. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2011;115:294–295.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Tramalloni D, Venturini PL, et al. Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-releasing intrauterine device. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2011;113:116–119.
   PubMed Web of Science ®Google Scholar
• Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gynaecol. 1992;99:212–215.
   PubMedGoogle Scholar
• Committee Opinion No. 663: aromatase Inhibitors in Gynecologic Practice. Obstet Gynecol. 2016;127:e170–174.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: estrogens play a role. Ann N Y Acad Sci. 2014;1317:17–23.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Grimm C, van Trotsenburg M, et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril. 2005;84:1033–1036.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau M-H, Waellnitz K, Nave R, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. Hum Reprod Oxf Eng. 2016;31:1713–1722.
   PubMed Web of Science ®Google Scholar
• Reinecke I, Schultze-Mosgau M-H, Nave R, et al. Model-based dose selection for intravaginal ring formulations releasing anastrozole and levonorgestrel intended for the treatment of endometriosis symptoms. J Clin Pharmacol. 2017;57:640–651.
   PubMed Web of Science ®Google Scholar
• Nave R. Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective. Drug Deliv. 2019;26:586–594.
   PubMed Web of Science ®Google Scholar
• Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97:14–21.
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Fernandes A, Monteiro I, et al. Long-acting reversible contraceptive (LARCs) methods. Best Pract Res Clin Obstet Gynaecol. 2020;66:28-40.
   Google Scholar
• Bl X, Ly Z, Xl Z, et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990; 41. [cited 2020 Jun 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/2335100/?from_single_result=Pharmacokinetic+and+pharmaco-+dynamic+studies+of+levonorgestrel-releasing+intrauterine+device
   Web of Science ®Google Scholar
• Viganò P, Somigliana E, Vercellini P. Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: biological and clinical evidence. Womens Health Lond Engl. 2007;3:207–214.
   PubMedGoogle Scholar
• Barbosa I, Olsson SE, Odlind V, et al. Ovarian function after seven years’ use of a levonorgestrel IUD. Adv Contracept Off J Soc Adv Contracept. 1995;11:85–95.
   PubMed Web of Science ®Google Scholar
• Grandi G, Farulla A, Sileo FG, et al. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19:677–686.
   PubMed Web of Science ®Google Scholar
• Yoo HJ, Lee MA, Ko YB, et al. The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrhea. Arch Gynecol Obstet. 2012;285:161–166.
   PubMed Web of Science ®Google Scholar
• Jt J, Al N, Ac C. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 2008; 77. [cited 2020 Jun 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/18082662/?from_single_result=Subject+and+clinician+experience+with+the+levonorgestrel-releasing+intrauterine+system
   Web of Science ®Google Scholar
• Buggio L, Somigliana E, Barbara G, et al. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother. 2017;18:1569–1581.
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril. 2001;75:485–488.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80:305–309.
   PubMed Web of Science ®Google Scholar
• Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119:519–526.
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod Oxf Eng. 2005;20:1993–1998.
   PubMed Web of Science ®Google Scholar
• Wong AYK, Tang LCH, Chin RKH. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2010;50:273–279.
   PubMed Web of Science ®Google Scholar
• Ferreira RA, Vieira CS, Rosa-E-Silva JC, et al. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010;81:117–122.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95:492–496.
   PubMed Web of Science ®Google Scholar
• Chen Y-J, Hsu T-F, Huang B-S, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol. 2017;216:582.e1-582.e9.
   Web of Science ®Google Scholar
• Carvalho N, Margatho D, Cursino K, et al. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018;110:1129–1136.
   PubMed Web of Science ®Google Scholar
• Morelli M, Sacchinelli A, Venturella R, et al. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J Obstet Gynaecol Res. 2013;39:985–990.
   PubMed Web of Science ®Google Scholar
• Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gynecol Scand. 2014;93:38–44.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan H, Deng L, et al. Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model. Hum Reprod Oxf Eng. 2008;23:2024–2030.
   PubMed Web of Science ®Google Scholar
• Cobellis L, Razzi S, Fava A, et al. A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril. 2004;82:239–240.
   PubMed Web of Science ®Google Scholar
• Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of long-acting reversible contraception. Drugs. 2011;71:969–980.
   PubMed Web of Science ®Google Scholar
• Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Contraception. 2016;94:202–215.
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol. 1996;175:396–401.
   PubMed Web of Science ®Google Scholar
• Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, et al. Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain: a randomized comparative trial. Gynecol Obstet Invest. 2012;74:151–156.
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod Oxf Eng. 2006;21:248–256.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006;85:314–325.
   PubMed Web of Science ®Google Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci Thousand Oaks Calif. 2014;21:1341–1351.
   PubMed Web of Science ®Google Scholar
• Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis–a pilot study. Contraception. 2009;79:29–34.
   PubMed Web of Science ®Google Scholar
• Modesto W, Bahamondes MV, Bahamondes L. Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate. J Womens Health. 2002 2015;24:636–640.
   Google Scholar
• Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81:281–291.
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–144.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception. 2008;78:459–464.
   PubMed Web of Science ®Google Scholar
• Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95:4909–4916.
   PubMed Web of Science ®Google Scholar
• Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121:593–600.
   PubMed Web of Science ®Google Scholar
• Committee Opinion No. 602: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2014;123:1398–1402.
   PubMedGoogle Scholar
• d’Arcangues C. WHO statement on hormonal contraception and bone health. Contraception. 2006;73:443–444.
   PubMed Web of Science ®Google Scholar
• McNicholas C, Swor E, Wan L, et al. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol. 2017;216:586.e1-586.e6.
   Web of Science ®Google Scholar
• Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thail Chotmaihet Thangphaet. 2005;88(Suppl 2):S7–10.
   PubMedGoogle Scholar
• Beerthuizen R, van Beek A, Massai R, et al. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod Oxf Eng. 2000;15:118–122.
   PubMed Web of Science ®Google Scholar
• Monteiro-Dantas C, Espejo-Arce X, Lui-Filho JF, et al. A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants. Reprod Health. 2007;4:11.
   PubMedGoogle Scholar
• Agarwal SK, Hamrang C, Henzl MR, et al. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. J Reprod Med. 1997;42:413–423.
   PubMed Web of Science ®Google Scholar
• Dawood MY, Spellacy WN, Dmowski WP, et al. A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 Study Group. Prog Clin Biol Res. 1990;323:253–267.
   PubMedGoogle Scholar
• Dmowski WP, Radwanska E, Binor Z, et al. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertil Steril. 1989;51:395–400.
   PubMed Web of Science ®Google Scholar
• Lemay A, Maheux R, Huot C, et al. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol. 1988;158:233–236.
   PubMed Web of Science ®Google Scholar
• Singh AK, Chakravarty B, Chaudhury K. Nanoparticle-assisted combinatorial therapy for effective treatment of endometriosis. J Biomed Nanotechnol. 2015;11:789–804.
   PubMed Web of Science ®Google Scholar
• Shakeri-Zadeh A, Khoei S, Khoee S, et al. Combination of ultrasound and newly synthesized magnetic nanocapsules affects the temperature profile of CT26 tumors in BALB/c mice. J Med Ultrason. 2015;42:9–16.
   PubMed Web of Science ®Google Scholar
• Irajirad R, Ahmadi A, Najafabad BK, et al. Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study. Cancer Chemother Pharmacol. 2019;84:1315–1321.
   PubMed Web of Science ®Google Scholar
• Mirrahimi M, Khateri M, Beik J, et al. Enhancement of chemoradiation by co-incorporation of gold nanoparticles and cisplatin into alginate hydrogel. J Biomed Mater Res B Appl Biomater. 2019;107:2658–2663.
   PubMed Web of Science ®Google Scholar
• Mirrahimi M, Abed Z, Beik J, et al. A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy. Pharmacol Res. 2019;143:178–185.
   PubMed Web of Science ®Google Scholar
• Martin TA, Jiang WG. Anti-Cancer agents in medicinal chemistry (Formerly current medicinal chemistry - Anti-cancer agents). Anticancer Agents Med Chem. 2010;18:438–449.
   Google Scholar
• Park K. Drug delivery of the future: chasing the invisible gorilla. J Control Release Off J Control Release Soc. 2016;240:2–8.
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377–1397.
   PubMed Web of Science ®Google Scholar
• de Almeida Borges VR, Tavares MR, da Silva JH, et al. Development and characterization of poly(lactic-co-glycolic) acid nanoparticles loaded with copaiba oleoresin. Pharm Dev Technol. 2018;23:343–350.
   PubMed Web of Science ®Google Scholar
• Liu Q, Ma P, Liu L, et al. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2017;96:542–550.
   PubMed Web of Science ®Google Scholar
• Nogueira Neto J, Lindoso MJ, Coelho LF, et al. Changes in the volume and histology of endometriosis foci in rats treated with copaiba oil (Copaiferalangsdorffii). Acta Cir Bras. 2011;26(Suppl 2):20–24.
   PubMedGoogle Scholar
• Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38:414–423.
   PubMed Web of Science ®Google Scholar
• Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol Baltim Md. 1950 2006;177:4376–4383.
   Google Scholar
• Basta P, Majka M, Jozwicki W, et al. The frequency of CD25+CD4+ and FOXP3+ regulatory T cells in ectopic endometrium and ectopic decidua. Reprod Biol Endocrinol RBE. 2010;8:116.
   PubMed Web of Science ®Google Scholar
• Podgaec S, Rizzo LV, Fernandes LFC, et al. CD4(+) CD25(high) Foxp3(+) cells increased in the peritoneal fluid of patients with endometriosis. Am J Reprod Immunol N Y N. 1989 2012;68:301–308.
   Google Scholar
• Ahn SH, Edwards AK, Singh SS, et al. IL-17A contributes to the pathogenesis of endometriosis by triggering proinflammatory cytokines and angiogenic growth factors. J Immunol Baltim Md. 1950 2015;195:2591–2600.
   Google Scholar
• Laganà AS, Salmeri FM, Ban Frangež H, et al. Evaluation of M1 and M2 macrophages in ovarian endometriomas from women affected by endometriosis at different stages of the disease. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2020;36:441-444.
   Google Scholar
• Capobianco A, Rovere-Querini P. Endometriosis, a disease of the macrophage. Front Immunol. 2013;4:9.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Li P. Experimental research on the treatment of mouse endometriosis model with nanoparticles loaded with CCR5-antibody. Zhonghua Fu Chan Ke Za Zhi. 2019;54:680–686.
   PubMedGoogle Scholar
• Antsiferova Y, Sotnikova N, Parfenyuk E. Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis. BioMed Res Int. 2013;2013:924362.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Iwamoto Y, Yanagihara Y, et al. Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice. Int J Immunopharmacol. 1992;14:1415–1420.
   PubMed Web of Science ®Google Scholar
• Coulombe F, Fiola S, Akira S, et al. Muramyl dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection. PloS One. 2012;7:e36734.
   PubMed Web of Science ®Google Scholar
• Bedin A, Maranhão RC, Tavares ER, et al. Nanotechnology for the treatment of deep endometriosis: uptake of lipid core nanoparticles by LDL receptors in endometriotic foci. Clinics. 2019;74. DOI:10.6061/clinics/2019/e989
   PubMed Web of Science ®Google Scholar
• Bayford R, Rademacher T, Roitt I, et al. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review. Physiol Meas. 2017;38:R183–R203.
   PubMed Web of Science ®Google Scholar
• Gibran L, Maranhão RC, Tavares ER, et al. mRNA levels of low-density lipoprotein receptors are overexpressed in the foci of deep bowel endometriosis. Hum Reprod Oxf Eng. 2017;32:332–339.
   PubMed Web of Science ®Google Scholar
• Guo X, Li W, Zhou J, et al. Specific photothermal ablation therapy of endometriosis by targeting delivery of gold nanospheres. Small Weinh Bergstr Ger. 2017;13.
   Google Scholar
• Moses AS, Taratula OR, Lee H, et al. Nanoparticle-based platform for activatable fluorescence imaging and photothermal ablation of endometriosis. Small Weinh Bergstr Ger. 2020;16:e1906936.
   PubMed Web of Science ®Google Scholar
• Rasouli R, Barhoum A, Bechelany M, et al. Nanofibers for biomedical and healthcare applications. Macromol Biosci. 2019;19:e1800256.
   PubMed Web of Science ®Google Scholar
• Boroumand S, Hosseini S, Pashandi Z, et al. Curcumin-loaded nanofibers for targeting endometriosis in the peritoneum of a mouse model. J Mater Sci Mater Med. 2019;31:8.
   PubMed Web of Science ®Google Scholar
• Arablou T, Kolahdouz-Mohammadi R. Curcumin and endometriosis: review on potential roles and molecular mechanisms. Biomed Pharmacother. 2018;97:91–97.
   PubMed Web of Science ®Google Scholar